Search

Crinetics Pharmaceuticals Inc

Aperta

SettoreSettore sanitario

83.54 -0.12

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

83.61

Massimo

83.79

Metriche Chiave

By Trading Economics

Entrata

-5M

-128M

Vendite

6.8M

11M

EPS

-1.23

Margine di Profitto

-1,191.029

Dipendenti

594

EBITDA

-5M

-127M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+2.31% upside

Dividendi

By Acuity

Utili prossimi

4 ago 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

4.5B

8.9B

Apertura precedente

83.66

Chiusura precedente

83.54

Notizie sul Sentiment di mercato

By Acuity

70%

30%

304 / 340 Classifica in Healthcare

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

30 lug 2026, 23:56 UTC

News

Old Dominion Freight Line shares lower in after-market hours after UBS raised its price target to $228 while maintaining a Neutral rating.

30 lug 2026, 23:56 UTC

News

DICK'S Sporting Goods Inc. sees gains in after-market trading, supported by solid fundamentals and recognition as a value stock despite mixed performance momentum.

30 lug 2026, 23:56 UTC

News

Viking Therapeutics Inc. shows a modest gain in after-market hours amid a wave of biopharmaceutical mergers, including Vertex's $10 billion acquisition of Crinetics.

30 lug 2026, 23:56 UTC

News

Check Point Software Technologies reported earnings of $2.55 per share, surpassing expectations of $2.45. Shares are little changed in after-market trading.

30 lug 2026, 23:52 UTC

News
Social Media

Amazon.com Inc shares rose in after-hours trading following strong second-quarter results, with net sales of $200.6 billion surpassing analyst expectations.

30 lug 2026, 23:51 UTC

News

Kimberly-Clark announced a $10 million commitment for recovery efforts in Wisconsin's Fox Valley, moving higher in after-market hours amid broader market gains.

30 lug 2026, 23:51 UTC

News

Boston Scientific shares are higher in after-market trading following UBS's Buy rating and a price target adjustment to $67 amid Penumbra's results.

30 lug 2026, 23:51 UTC

News

Castle Biosciences reported second-quarter revenues of $103.5 million, exceeding estimates. Shares are sharply higher in after-market trading following the earnings and guidance update.

30 lug 2026, 23:51 UTC

News

Hercules Capital reported second-quarter earnings of $0.50 per share, exceeding estimates. Shares are higher in after-market trading following the strong results.

30 lug 2026, 23:51 UTC

Correlated Moves
News

EMCOR Group Inc. reported record second-quarter results, with revenue of $5.15 billion and EPS of $9.06, raising full-year guidance. Shares are higher in after-market hours.

30 lug 2026, 23:51 UTC

Social Media
Correlated Moves
News

Lam Research Corp shares rose in after-market hours following strong second-quarter results, with adjusted EPS of $1.82 and optimistic third-quarter revenue guidance of $8.1 billion.

30 lug 2026, 23:51 UTC

News
Social Media

Dexcom reported second-quarter revenue of $1.308 billion and adjusted EPS of $0.70, raising its fiscal year 2026 revenue guidance, with shares trading higher in after-market hours.

30 lug 2026, 23:51 UTC

News
Social Media

Roblox Corp shares fell in after-hours trading following a narrower net loss of $183 million but disappointing revenue and guidance for third-quarter bookings.

30 lug 2026, 23:51 UTC

News
Social Media

Replimune Group shares are advancing in after-market trading following a favorable FDA advisory vote on its melanoma treatment RP1, despite earlier declines during the session.

30 lug 2026, 23:51 UTC

News
Event
Social Media

Apple Inc reported fiscal Q3 revenue of $109.4 billion, but shares fell in after-hours trading due to weaker-than-expected guidance and missed services revenue.

30 lug 2026, 23:46 UTC

News

TFS Financial Corp reported third-quarter EPS of $0.11, surpassing estimates. Shares are higher in after-market trading following strong earnings and revenue results.

30 lug 2026, 23:46 UTC

News

Eastman Chemical Co reported second-quarter net earnings of $183 million, up from $140 million last year, with shares trading roughly flat in after-market hours.

30 lug 2026, 23:46 UTC

Correlated Moves
News

UBS raised its price target on Xylem Inc. to $135, as shares traded higher in after-market hours following a dip earlier in the session.

30 lug 2026, 23:46 UTC

Social Media
News

Yum Brands reported a cyclospora outbreak linked to Taco Bell affecting sales. Shares are trading higher in after-market hours, continuing recent upward momentum.

30 lug 2026, 23:46 UTC

News

Shares of Netflix are lower in after-market trading following Anne Sweeney's resignation from the board, confirmed not to be due to any disagreement.

30 lug 2026, 23:41 UTC

News

CareDx Inc reported second-quarter revenue of $132 million, exceeding estimates. Following strong results and raised guidance, shares are higher in after-market trading.

30 lug 2026, 23:41 UTC

Social Media
Event
News

Karyopharm Therapeutics shares fell sharply after its Phase 3 trial for selinexor failed to meet key endpoints, leading to a shift in focus away from endometrial cancer.

30 lug 2026, 23:41 UTC

Social Media
Correlated Moves
News

MicroStrategy reported a second-quarter loss of $8.62 billion, significantly missing expectations. Shares are trading higher in after-market hours amid broader market gains.

30 lug 2026, 23:41 UTC

News
Social Media

Illumina Inc shares declined in after-market trading despite strong second-quarter results and raised full-year EPS guidance, reflecting concerns over falling net income.

30 lug 2026, 23:41 UTC

Social Media
News

Stryker Corp shares fell in after-market trading despite reporting adjusted EPS of $3.69 and raising full-year guidance to $14.95 to $15.10.

30 lug 2026, 23:41 UTC

News

Cerus Corporation shares declined in after-market hours following a revenue miss and lowered full-year guidance, despite second-quarter earnings matching estimates.

30 lug 2026, 23:41 UTC

News

Cognizant Technology Solutions shares are lower in after-market trading despite stable revenue and increased profit guidance in its recent second-quarter update.

30 lug 2026, 23:41 UTC

Correlated Moves
News
Social Media

Micron Technology's after-market hours trading rises significantly, driven by a broader market rally and a $153 billion increase in market capitalization.

30 lug 2026, 23:41 UTC

News

Bloom Energy Corp shares are higher in after-market hours, driven by strong performance in the Heavy Electrical Equipment sector and significant revenue growth.

30 lug 2026, 23:41 UTC

News

PTC Inc. gained in after-market hours, driven by strong quarterly results and raised revenue guidance, reaching a high of 2.82% since Thursday's close.

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

2.31% in crescita

Previsioni per 12 mesi

Media 85.56 USD  2.31%

Alto 95 USD

Basso 80 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

14 ratings

2

Acquista

12

Mantieni

0

Vendi

Sentiment

By Acuity

304 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat